DK1446136T3 - Curcuminoide sammensætninger med synergistisk inhibering af ekspressionen og/eller aktiviteten af cyclooxygenase-2 gen - Google Patents

Curcuminoide sammensætninger med synergistisk inhibering af ekspressionen og/eller aktiviteten af cyclooxygenase-2 gen

Info

Publication number
DK1446136T3
DK1446136T3 DK02784313.5T DK02784313T DK1446136T3 DK 1446136 T3 DK1446136 T3 DK 1446136T3 DK 02784313 T DK02784313 T DK 02784313T DK 1446136 T3 DK1446136 T3 DK 1446136T3
Authority
DK
Denmark
Prior art keywords
cyclooxygenase
gene
expression
activity
synergistic inhibition
Prior art date
Application number
DK02784313.5T
Other languages
English (en)
Inventor
John G Babish
Terrence Howell
Linda Pacioretty
Original Assignee
Metaproteomics Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Metaproteomics Llc filed Critical Metaproteomics Llc
Application granted granted Critical
Publication of DK1446136T3 publication Critical patent/DK1446136T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/348—Cannabaceae
    • A61K36/3486—Humulus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/906—Zingiberaceae (Ginger family)
    • A61K36/9066—Curcuma, e.g. common turmeric, East Indian arrowroot or mango ginger
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Botany (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DK02784313.5T 2001-10-26 2002-10-25 Curcuminoide sammensætninger med synergistisk inhibering af ekspressionen og/eller aktiviteten af cyclooxygenase-2 gen DK1446136T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33506201P 2001-10-26 2001-10-26
PCT/US2002/034456 WO2003035007A2 (en) 2001-10-26 2002-10-25 Curcuminoid compositions exhibiting synergistic inhibition of the expression and/or activity of cyclooxygenase-2

Publications (1)

Publication Number Publication Date
DK1446136T3 true DK1446136T3 (da) 2011-01-10

Family

ID=23310091

Family Applications (1)

Application Number Title Priority Date Filing Date
DK02784313.5T DK1446136T3 (da) 2001-10-26 2002-10-25 Curcuminoide sammensætninger med synergistisk inhibering af ekspressionen og/eller aktiviteten af cyclooxygenase-2 gen

Country Status (14)

Country Link
US (1) US20030096027A1 (da)
EP (2) EP2253314A3 (da)
JP (3) JP2005506996A (da)
KR (1) KR20040054738A (da)
AT (1) ATE482696T1 (da)
AU (2) AU2002348096B2 (da)
CA (1) CA2464334C (da)
DE (1) DE60237836D1 (da)
DK (1) DK1446136T3 (da)
ES (1) ES2353868T3 (da)
MX (1) MXPA04003734A (da)
NZ (1) NZ532560A (da)
PT (1) PT1446136E (da)
WO (1) WO2003035007A2 (da)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040266883A1 (en) * 1999-10-27 2004-12-30 Yale University Conductance of improperly folded proteins through the secretory pathway and related methods for treating disease
US20030149113A1 (en) 2001-10-12 2003-08-07 Caplan Michael J. Conductance of improperly folded proteins through the secretory pathway and related methods for treating disease
US20020076452A1 (en) * 2000-08-01 2002-06-20 Ashni Naturaceuticals, Inc. Combinations of sesquiterpene lactones and ditepene lactones or triterpenes for synergistic inhibition of cyclooxygenase-2
US20040115290A1 (en) 2001-06-20 2004-06-17 Tripp Matthew L. Modulation of inflammation by hops fractions and derivatives
US7718198B2 (en) * 2001-06-20 2010-05-18 Metaproteomics, Llc Treatment modalities for autoimmune diseases
US8168234B2 (en) 2001-06-20 2012-05-01 Metaproteomics, Llc Compositions that treat or inhibit pathological conditions associated with inflammatory response
US7205151B2 (en) * 2001-06-20 2007-04-17 Metaproteomics, Llc Complex mixtures exhibiting selective inhibition of cyclooxygenase-2
US8142819B2 (en) 2002-10-21 2012-03-27 Metaproteomics, Llc Synergistic compositions that treat or inhibit pathological conditions associated with inflammatory response
US7666449B2 (en) * 2001-06-20 2010-02-23 Metaproteomics, Llc Anti-inflammatory pharmaceutical compositions for reducing inflammation and the treatment or prevention of gastric toxicity
US8206753B2 (en) * 2001-06-20 2012-06-26 Metaproteomics, Llc Anti-inflammatory botanical products for the treatment of metabolic syndrome and diabetes
US7901714B2 (en) * 2001-06-20 2011-03-08 Metaproteomics, Llp Treatment modalities for autoimmune diseases
US7901713B2 (en) * 2001-06-20 2011-03-08 Metaproteomics, Llc Inhibition of COX-2 and/or 5-LOX activity by fractions isolated or derived from hops
US7270835B2 (en) * 2001-06-20 2007-09-18 Metaproteomics, Llc Compositions that treat or inhibit pathological conditions associated with inflammatory response
US7279185B2 (en) 2001-10-26 2007-10-09 Metaproteonics, Llc Curcuminoid compositions exhibiting synergistic inhibition of the expression and/or activity of cyclooxygenase-2
JP2005506996A (ja) * 2001-10-26 2005-03-10 メタプロテオミクス， エルエルシー シクロオキシゲナーゼ−２の発現および／または活性の相乗的阻害を示すクルクミノイド組成物
US8158160B2 (en) 2001-11-13 2012-04-17 Eric Hauser Kuhrts Anti-inflammatory cyclooxygenase inhibitors
AU2003211997B2 (en) * 2002-02-14 2009-01-29 Kirin Beer Kabushiki Kaisha Compositions and foods for improving lipid metabolism
CA2483340A1 (en) * 2002-04-24 2003-11-06 Research Development Foundation Synergistic effects of nuclear transcription factor nf-.kappa.b inhibitors and anti-neoplastic agents
AU2003253681B2 (en) * 2002-06-24 2008-05-01 Research Development Foundation Treatment of human multiple myeloma by Curcumin
EP1558271A4 (en) * 2002-10-21 2006-01-11 Metaproteomics Llc COMPOSITIONS FOR TREATING OR INHIBITING PATHOLOGICAL CONDITIONS IN CONNECTION WITH AN INFLAMMATORY ANSWER
JP2005104951A (ja) * 2003-01-17 2005-04-21 Kirin Brewery Co Ltd 血圧降下用組成物および血管柔軟性改善用組成物並びにこれらの機能が付与された食品
MXPA05012584A (es) * 2003-05-22 2006-05-25 Metaproteomics Llc Composiciones farmaceuticas anti-inflamatorias para disminuir la inflamacion, y tratamiento o prevencion de toxicidad gastrica.
ITMI20031098A1 (it) * 2003-05-30 2004-11-30 Indena Spa Composti utili nella terapia del morbo di alzheimer e formulazioni che li contengono
EP1694335A4 (en) * 2003-08-26 2008-12-31 Res Dev Foundation OSTEOCLASTOGENESIS INHIBITORS AND USES THEREOF
JP2005154390A (ja) * 2003-11-28 2005-06-16 Morishita Jintan Kk 肝保護剤
US7914831B2 (en) * 2004-02-27 2011-03-29 Metaproteomics, Llc Synergistic anti-inflammatory pharmaceutical compositions and related methods using curcuminoids or methylxanthines
US20050192356A1 (en) 2004-02-27 2005-09-01 Babish John G. Synergistic anti-inflammatory pharmaceutical compositions and methods of use
AU2011202586B2 (en) * 2004-02-27 2012-03-22 Metaproteomics, Llc Synergistic anti-inflammatory pharmaceutical compositions and related methods using curcuminoids or methylxanthines
JPWO2006043671A1 (ja) * 2004-10-22 2008-05-22 キリンホールディングス株式会社 転写因子Ｎｒｆ２活性化剤およびその機能が付与された食品
EP1817941A4 (en) * 2004-11-13 2009-11-11 Metaproteomics Llc CYCLOOXYGENASE-2 INHIBITION COMPOSITIONS
WO2007021694A2 (en) * 2005-08-09 2007-02-22 Metaproteomics, Llc Protein kinase modulation by hops and acacia products
CA2632684A1 (en) * 2005-12-09 2007-06-14 Metaproteomics, Llc Protein kinase modulation by hops and acacia products
US7919531B2 (en) * 2006-05-24 2011-04-05 Dsm Ip Assets B.V. 3,5-dihydroxy-2,4-cyclohexadienones and their derivatives, dietary compositions and fortified food containing them and their uses
EP2046355A4 (en) * 2006-06-20 2010-02-03 Metaproteomics Llc REDUCED ISOALPHIC ACID BASED PROTEIN CHINESE MODULATION AS CANCER TREATMENT
US20080051466A1 (en) * 2006-06-20 2008-02-28 Metaproteomics, Llc Isoalpha acid based protein kinase modulation cancer treatment
WO2008048410A2 (en) * 2006-09-19 2008-04-24 Human Biomolecular Research Institute Diagnostic methods and genetic markers for alzheimer disease
JP2010522190A (ja) * 2007-03-19 2010-07-01 メタプロテオミクス， エルエルシー 骨及び関節の健康を助成するための方法と組成物
WO2008120220A1 (en) * 2007-04-03 2008-10-09 Ganga Raju Gokaraju Synergistic anti-inflammatory and antioxidant dietary supplement compositions
WO2008140842A1 (en) 2007-05-11 2008-11-20 Metaproteomics, Llc Methods and compositions for heavy metal detoxification
WO2009066303A2 (en) * 2007-11-22 2009-05-28 Ganga Raju Gokaraju New synergistic phytochemical composition for the treatment of obesity
CN101969972A (zh) * 2007-12-10 2011-02-09 麦特普罗泰欧米克斯有限公司 癌症、血管生成、以及与其相关的炎症通路的取代的1,3-环戊二酮多靶点蛋白激酶调节剂
MX2010010791A (es) * 2008-04-02 2011-03-04 Metaproteomics Llc Star Inflamación endotelial atenuada por 1,3-ciclopentadiona substituida e interacciones endoteliales-monocito.
CA2719799A1 (en) * 2008-04-11 2009-10-15 Betal, Llc Xanthohumol compositions and methods for treating skin diseases or disorders
EP2799069A4 (en) 2011-12-28 2015-12-23 Maruha Nichiro Corp DEGRANULATION INHIBITOR WITH CHLOROPHYLL C
JP6163084B2 (ja) * 2013-11-11 2017-07-12 キリン株式会社 認知症の予防、治療及び／又は認知機能を改善する組成物、及びこれを用いた医薬、食品
JP6242746B2 (ja) * 2014-05-26 2017-12-06 キリン株式会社 記憶学習機能を向上する医薬、食品、組成物
CN107582962A (zh) * 2017-06-01 2018-01-16 合肥远志医药科技开发有限公司 一种用于慢性萎缩性胃炎的配方及其提取工艺
US20230241006A1 (en) * 2019-12-03 2023-08-03 Omniactive Health Technologies Limited Curcumin compositions for osteoarthritis and joint wellness

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07149628A (ja) * 1993-11-30 1995-06-13 Suntory Ltd 脂質代謝改善剤
US5494668A (en) * 1994-07-11 1996-02-27 Patwardhan; Bhushan Method of treating musculoskeletal disease and a novel composition therefor
JPH0873369A (ja) * 1994-09-01 1996-03-19 Fuairudo:Kk 健康茶
US6346519B1 (en) * 1998-09-09 2002-02-12 Advanced Medical Instruments Method and composition for treating arthritis
US20010051184A1 (en) * 1999-05-20 2001-12-13 Madalene C.Y. Heng Method for using soluble curcumin to inhibit phosphorylase kinase in inflammatory diseases
US6143303A (en) * 1999-08-14 2000-11-07 Janakiram; Chodavarapu Analgesic anti-inflammatory composition and method of preparing from dodonaea sp
DE10031955A1 (de) * 2000-06-30 2002-01-17 Deutsches Krebsforsch Curcumin-Derivate mit gegenüber Curcumin verbesserter Wasserlöslichkeit und diese enthaltende Arzneimittel
US6391346B1 (en) * 2001-04-05 2002-05-21 Thomas Newmark Anti-inflammatory, sleep-promoting herbal composition and method of use
JP2005506996A (ja) * 2001-10-26 2005-03-10 メタプロテオミクス， エルエルシー シクロオキシゲナーゼ−２の発現および／または活性の相乗的阻害を示すクルクミノイド組成物
US7914831B2 (en) * 2004-02-27 2011-03-29 Metaproteomics, Llc Synergistic anti-inflammatory pharmaceutical compositions and related methods using curcuminoids or methylxanthines

Also Published As

Publication number Publication date
JP2011068680A (ja) 2011-04-07
CA2464334C (en) 2012-01-10
ATE482696T1 (de) 2010-10-15
EP1446136B1 (en) 2010-09-29
AU2008202916B8 (en) 2010-06-10
CA2464334A1 (en) 2003-05-01
MXPA04003734A (es) 2005-06-20
AU2008202916B2 (en) 2010-06-03
WO2003035007A2 (en) 2003-05-01
ES2353868T3 (es) 2011-03-07
JP2005506996A (ja) 2005-03-10
EP2253314A2 (en) 2010-11-24
NZ532560A (en) 2005-02-25
KR20040054738A (ko) 2004-06-25
AU2002348096B2 (en) 2008-04-03
EP1446136A2 (en) 2004-08-18
EP1446136A4 (en) 2007-01-10
EP2253314A3 (en) 2012-08-01
WO2003035007A3 (en) 2003-09-18
PT1446136E (pt) 2010-12-29
JP2011093918A (ja) 2011-05-12
DE60237836D1 (de) 2010-11-11
AU2008202916A1 (en) 2008-07-24
US20030096027A1 (en) 2003-05-22

Similar Documents

Publication Publication Date Title
DK1446136T3 (da) Curcuminoide sammensætninger med synergistisk inhibering af ekspressionen og/eller aktiviteten af cyclooxygenase-2 gen
EA200700382A1 (ru) Фунгицидные композиции
CY1119601T1 (el) Προαγωγεις αποπτωσης
DE60329316D1 (de) Phenylcarboxamide als beta-sekretase-hemmer zur behandlung von alzheimer
DK1663185T3 (da) Forebyggelse og behandling af inflammationsinduceret og/eller immun-medieret knogletab
BRPI0407587A (pt) inibidores do vìrus da hepatite c, composições e tratamentos que os utilizam
ATE515261T1 (de) Zusammensetzungen zur behandlung von diabetes
DK1005271T3 (da) Synergistisk biocidsammensætning
BR0004884A (pt) Composições acaricidas
ATE447574T1 (de) 3-amino-4-phenylbutansäurederivate als dipeptidylpeptidase-hemmer zur behandlung oder vorbeugung von diabetes
BR0011433B1 (pt) Compostos de imidazoquinolinas substituídas com sulfonamida e sulfamida e composição farmaceutica cotendo os mesmos
PL402389A1 (pl) Sposób hamowania aktywnosci kinazy Raf u ludzi lub zwierzat
UA88463C2 (ru) Фармацевтическая композиция, которая содержит соединение 1, и процесс лечения вич-инфекции
ATE293691T1 (de) Myostatin genpromoter und inhibierung dessen aktivierung
ATE409065T1 (de) Inhibitoren der 17 beta- hydroxysteroiddehydrogenase des typs 3 zur behandlung androgenabhängiger krankheiten
BRPI0416030A (pt) pirido-7-pirimidin-7-onas substituìdas com hidroxialquila
ATE554753T1 (de) 2,2'-dithio-bis(ethansulfonat) für den einsatz zur hemmung paclitaxel-induzierter abnormer thermoesthesia
DE602004031435D1 (de) Cycloalkyl-heterozyklen zur behandlung des hepatitis-c-virus
EA200870195A1 (ru) Новые композиции пестицидов
ATE526056T1 (de) Igf-2 peptid zur verwendung in einer tolerogenen behandlung für typ i diabetes
WO2004006911A3 (fr) Compositions destinees au traitement des neuropathies peripheriques, preparation et utilisations
BRPI0411168A (pt) composição para o tratamento dos cabelos, usos de uma composição e método de tratamento dos cabelos
WO2002096870A3 (en) Sponge-derived terpenoids and methods of use
DK1734996T3 (da) Fremgangsmåder og sammensætninger til behandling og forebyggelse af sygdom, der er associeret med alfa v beta 5-integrin
ATE472316T1 (de) Haarbehandlungszusammensetzungen